STAAR Surgical (Nasdaq: STAA) reported earnings on July 31. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 28 (Q2), STAAR Surgical beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded. Non-GAAP earnings per share expanded significantly. GAAP earnings per share expanded.

Margins expanded across the board.

Revenue details
 STAAR Surgical logged revenue of $18.2 million. The five analysts polled by S&P Capital IQ anticipated revenue of $17.4 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $15.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at $0.05. The two earnings estimates compiled by S&P Capital IQ anticipated $0.04 per share. Non-GAAP EPS of $0.05 for Q2 were 67% higher than the prior-year quarter's $0.03 per share. GAAP EPS were $0.01 for Q2 versus -$0.01 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 69.5%, 20 basis points better than the prior-year quarter. Operating margin was 3.8%, 50 basis points better than the prior-year quarter. Net margin was 1.5%, 460 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $17.3 million. On the bottom line, the average EPS estimate is $0.04.

Next year's average estimate for revenue is $70.7 million. The average EPS estimate is $0.16.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 81 members out of 91 rating the stock outperform, and 10 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give STAAR Surgical a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is outperform, with an average price target of $9.75.

Looking for alternatives to STAAR Surgical? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.